Railway Pension Investments Ltd Purchases 42,200 Shares of Gilead Sciences, Inc. $GILD

Railway Pension Investments Ltd increased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,415,665 shares of the biopharmaceutical company’s stock after acquiring an additional 42,200 shares during the period. Gilead Sciences comprises about 2.1% of Railway Pension Investments Ltd’s investment portfolio, making the stock its 21st biggest holding. Railway Pension Investments Ltd owned 0.11% of Gilead Sciences worth $157,139,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Earned Wealth Advisors LLC boosted its position in Gilead Sciences by 3.5% in the third quarter. Earned Wealth Advisors LLC now owns 5,322 shares of the biopharmaceutical company’s stock worth $591,000 after purchasing an additional 179 shares during the last quarter. Asset Management One Co. Ltd. lifted its stake in shares of Gilead Sciences by 1.9% in the 3rd quarter. Asset Management One Co. Ltd. now owns 727,196 shares of the biopharmaceutical company’s stock worth $80,719,000 after purchasing an additional 13,719 shares during the period. Gateway Investment Advisers LLC lifted its stake in shares of Gilead Sciences by 57.7% in the 3rd quarter. Gateway Investment Advisers LLC now owns 119,323 shares of the biopharmaceutical company’s stock worth $13,245,000 after purchasing an additional 43,672 shares during the period. Fifth Third Wealth Advisors LLC boosted its holdings in shares of Gilead Sciences by 6.0% in the third quarter. Fifth Third Wealth Advisors LLC now owns 13,535 shares of the biopharmaceutical company’s stock worth $1,502,000 after buying an additional 772 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC grew its position in Gilead Sciences by 4.1% during the third quarter. Moss Adams Wealth Advisors LLC now owns 4,370 shares of the biopharmaceutical company’s stock valued at $485,000 after buying an additional 172 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, December 15th. The shares were sold at an average price of $122.00, for a total value of $366,000.00. Following the sale, the chief financial officer directly owned 153,503 shares in the company, valued at approximately $18,727,366. The trade was a 1.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the transaction, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at $69,389,826.17. This trade represents a 1.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 136,257 shares of company stock valued at $16,855,192 in the last ninety days. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $121.60 on Monday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The business has a 50-day moving average price of $123.05 and a 200-day moving average price of $117.17. The firm has a market cap of $150.87 billion, a price-to-earnings ratio of 18.85, a price-to-earnings-growth ratio of 0.65 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the previous year, the firm earned $2.02 EPS. The firm’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were given a dividend of $0.79 per share. The ex-dividend date was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on GILD. Rothschild & Co Redburn increased their price target on shares of Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. The Goldman Sachs Group boosted their price objective on shares of Gilead Sciences from $108.00 to $110.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Daiwa Capital Markets raised their target price on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a report on Thursday, November 13th. Mizuho boosted their price target on Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Finally, Wells Fargo & Company raised their price objective on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $131.68.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.